Vivos Therapeutics (VVOS) Cash & Equivalents Growth (1y) (2020 - 2026)
Vivos Therapeutics (VVOS) Cash & Equivalents Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 4.15% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 24.05% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 100.41% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -22.13% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 23.57% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -7.71% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | -10.02% |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 141.82% |
| 10 | Vivos Therapeutics | 5.92 Mn | 3.81 Mn | 3.06 Mn | -8.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.26% |
| Dec 31, 2025 | -67.59% |
| Sep 30, 2025 | -50.79% |
| Jun 30, 2025 | -36.23% |
| Mar 31, 2025 | -11.54% |
| Dec 31, 2024 | 281.01% |
| Sep 30, 2024 | 537.65% |
| Jun 30, 2024 | 76.92% |
| Mar 31, 2024 | -62.86% |
| Dec 31, 2023 | -53.31% |
| Sep 30, 2023 | -85.30% |
| Jun 30, 2023 | -69.20% |
| Mar 31, 2023 | -60.74% |
| Dec 31, 2022 | -85.34% |
| Sep 30, 2022 | -76.42% |
| Jun 30, 2022 | -62.98% |
| Mar 31, 2022 | 26.44% |
| Dec 31, 2021 | 31.82% |
| Dec 31, 2020 | 3,778.96% |